Gpam (mouse, Q61586) review notes

2026-10-20 — Full re-review, independent of the ProtNLM2 predictions

Context: mouse Gpam is the experimentally characterised ortholog of the ProtNLM2
benchmark gene human GPAM (Q9HCL2). This review was written without opening any
ProtNLM2 prediction file and does not use ProtNLM2 output as evidence.

Process / provenance

Evolutionary grounding

What is experimentally established in mouse itself

  1. Loss of NEM-resistant (mitochondrial) GPAT activity in Gpam-/- liver
    PMID:12417724 and dose
    dependent loss of activity after hepatic shRNA knockdown in ob/ob mice PMID:16935266.
    Together with activity of the recombinant mouse enzyme cited in PMID:12417724
    (palmitoyl-CoA preference, 5.5-fold over 18:1-CoA in Sf9 cells), this establishes
    GO:0004366 in mouse.
  2. TAG synthesis: Gpam-/- mice have lower hepatic and plasma TAG and reduced VLDL-TAG
    secretion PMID:12417724; hepatocytes lacking GPAT1 cannot incorporate de novo
    synthesised fatty acid into TAG PMID:23908354; hearts of Gpat1-/- mice on
    lipogenic diets accumulate 20-80% less TAG PMID:18522808.
  3. Fatty acid partitioning: without GPAT1, acyl-CoAs are diverted to beta-oxidation
    and ketogenesis and hepatic acyl-CoA rises [PMID:15878874, PMID:23908354].
  4. sn-1 palmitate positioning in liver/heart PC and PE, with secondary increase of sn-2
    arachidonate [PMID:12417724, PMID:18522808].
  5. Location: mouse-specific direct localization data are limited to organelle
    proteomics (mitochondrion; PMID:14651853, PMID:18614015) and the inner-membrane
    proteomic list PMID:12865426. Outer-membrane placement rests on rat liver
    subfractionation [PMID:17493869: active pool in OMM; import into mitochondria but
    not microsomes] and the human cryo-EM structure [PMID:36522428: no TM helices,
    amphipathic patch + N-terminal targeting loop-helix]. OMM is therefore
    orthologue-inferred for mouse, but the inference is strong (same subfamily).

Annotation decisions (summary)

Open questions